Internal Medicine, Hematology & Oncology · Walnut Creek, CA
NPI
1164643359
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
500 Lennon Ln
Walnut Creek, CA, 94598
Phone (925) 939-9610
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.1M
425,291 services
Medicare patients, 2024
800
Average age 77
Drug cost, 2024
$10.5M
1,637 prescriptions
Company payments, 2025
$9,269
From 73 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael P Sherman was code J0641 (injection, levoleucovorin, not otherwise specified, 0.5 mg), 75,892 times for 12 patients. In total Michael P Sherman billed 425,291 services in 152 codes, and Medicare paid $8.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-09-23.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0641 Injection, levoleucovorin, not otherwise specified, 0.5 mg | Office | 75,892 | 12 | $0.07 | $5,359 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 56,250 | 36 | $0.86 | $48K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 55,200 | 48 | $2.33 | $129K |
| J0897 Injection, denosumab, 1 mg | Office | 35,940 | 110 | $20.53 | $738K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 21,200 | 18 | $44.60 | $946K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 20,700 | 26 | $0.11 | $2,275 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,375 | 44 | $0.10 | $639 |
| J2796 Injection, romiplostim, 10 micrograms | Office | 5,117 | 20 | $78.01 | $399K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,944 | 41 | $0.09 | $266 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 2,940 | 23 | $0.25 | $735 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,610 | 31 | $0.69 | $1,801 |
| 99214 Office E&M - Established | Office | 1,457 | 457 | $122.17 | $178K |
| 99215 Office E&M - Established | Office | 1,335 | 324 | $173.02 | $231K |
| J9190 Injection, fluorouracil, 500 mg | Office | 1,010 | 12 | $2.27 | $2,295 |
| 96372 Injection Administration | Office | 972 | 172 | $14.39 | $14K |
By year: 2022 $7.1M for 484,481 services; 2023 $8.1M for 419,715 services; 2024 $8.1M for 425,291 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael P Sherman prescribed most often to Medicare patients was Xgeva (Denosumab), with 179 prescriptions and refills. In total Michael P Sherman wrote 1,637 Medicare prescriptions that cost $10.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xgeva Denosumab | 179 | 179 | 28 | $566K |
| Aranesp Darbepoetin Alfa In Polysorbat | 172 | 172 | 39 | $421K |
| Abiraterone Acetate Generic | 127 | 141 | 23 | $344K |
| Prednisone Generic | 126 | 146 | 26 | $574 |
| Xtandi Enzalutamide | 103 | 103 | 17 | $1.4M |
| Calquence Acalabrutinib Maleate | 51 | 51 | Under 11 | $719K |
| Brukinsa Zanubrutinib | 49 | 49 | Under 11 | $722K |
| Lupron Depot Leuprolide Acetate | 48 | 163 | 20 | $325K |
| Erleada Apalutamide | 48 | 50 | Under 11 | $689K |
| Nubeqa Darolutamide | 39 | 39 | Under 11 | $511K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 30 | 30 | Under 11 | $284K |
| Lynparza Olaparib | 29 | 29 | Under 11 | $431K |
| Neulasta Onpro Pegfilgrastim | 29 | 29 | Under 11 | $181K |
| Hydroxyurea Generic | 27 | 49 | Under 11 | $596 |
| Orgovyx Relugolix | 26 | 26 | Under 11 | $70K |
Brand drugs: 1,132 claims; generic drugs: 505 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael P Sherman $9,269 ($9,269 in general payments such as food, travel and fees) from 73 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $773.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 26 | $773 |
| Janssen Biotech, Inc. JNJ | 35 | $680 |
| Daiichi Sankyo Inc. 4568.T | 21 | $465 |
| Merck Sharp & Dohme LLC MRK | 16 | $443 |
| Pfizer Inc. PFE | 24 | $408 |
| Celgene Corporation BMY | 24 | $316 |
| Genentech USA, Inc. ROG.SW | 13 | $315 |
| GlaxoSmithKline, LLC. GSK | 16 | $312 |
| US Oncology Corporate, Inc. | 1 | $299 |
| E.R. Squibb & Sons, L.L.C. BMY | 25 | $276 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.